These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33388397)

  • 21. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.
    Marquis-Gravel G; Dalgaard F; Jones AD; Lokhnygina Y; James SK; Harrington RA; Wallentin L; Steg PG; Lopes RD; Storey RF; Goodman SG; Mahaffey KW; Tricoci P; White HD; Armstrong PW; Ohman EM; Alexander JH; Roe MT
    J Am Coll Cardiol; 2020 Jul; 76(2):162-171. PubMed ID: 32646565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
    Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
    Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The underutilisation of dual antiplatelet therapy in acute coronary syndrome.
    Anastasius M; Lau JK; Hyun K; D'Souza M; Patel A; Rankin J; Walters D; Juergens C; Aliprandi-Costa B; Yan AT; Goodman SG; Chew D; Brieger D
    Int J Cardiol; 2017 Aug; 240():30-36. PubMed ID: 28476519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischaemic risk with bleeding risk?
    Fake AL; Harding SA; Matsis PP; Larsen PD
    N Z Med J; 2016 May; 129(1435):39-49. PubMed ID: 27355167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Misumida N; Abo-Aly M; Kim SM; Ogunbayo GO; Abdel-Latif A; Ziada KM
    Clin Cardiol; 2018 Nov; 41(11):1455-1462. PubMed ID: 30225978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comments on "Sex differences in distribution, management and outcomes of combined ischemic bleeding risk following acute coronary syndrome".
    Verdoia M; De Luca G
    Int J Cardiol; 2021 May; 331():8-9. PubMed ID: 33515612
    [No Abstract]   [Full Text] [Related]  

  • 29. Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
    Choi SY; Kim MH; Cho YR; Sung Park J; Min Lee K; Park TH; Yun SC
    Circ Cardiovasc Interv; 2018 Dec; 11(12):e006837. PubMed ID: 30545256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive value of the CRUSADE score to the GRACE score for mortality risk prediction in patients with acute coronary syndromes.
    Cordero A; Rodriguez-Manero M; García-Acuña JM; López-Palop R; Cid B; Carrillo P; Agra-Bermejo R; González-Salvado V; Iglesias-Alvarez D; Bertomeu-Martínez V; González-Juanatey JR
    Int J Cardiol; 2017 Oct; 245():1-5. PubMed ID: 28789846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
    Moalem K; Baber U; Chandrasekhar J; Claessen BE; Sartori S; Aquino M; Dangas G; Iakovou I; Colombo A; Kini A; Gibson M; Krucoff M; Chieffo A; Moliterno D; Witzenbichler B; Pocock S; Mehran R
    Clin Res Cardiol; 2019 Jun; 108(6):643-650. PubMed ID: 30607496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving risk stratification in non-ST-segment elevation myocardial infarction with combined assessment of GRACE and CRUSADE risk scores.
    Paiva L; Providência R; Barra SN; Dinis P; Faustino AC; Costa M; Gonçalves L
    Arch Cardiovasc Dis; 2014 Dec; 107(12):681-9. PubMed ID: 25219759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twelve-month outcomes of patients unsuitable for prolonged DAPT presenting with an acute coronary syndrome and treated with polymer-free biolimus A9 drug-coated stents.
    Kinnaird T; Abdul F; Hailan A; Sheikh A; Hinton J; Yazji K; Elangovan S; Yousef A; Gallagher S; Choudhury A; Anderson R; O'Kane P; Smith D
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):1220-1228. PubMed ID: 30244504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasive Management Strategies and Antithrombotic Treatments in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome in China: Findings From the Improving CCC Project (Care for Cardiovascular Disease in China).
    Yang Q; Wang Y; Liu J; Liu J; Hao Y; Smith SC; Huo Y; Fonarow GC; Ma C; Ge J; Taubert KA; Morgan L; Guo Y; Wang W; Zhou Y; Zhao D;
    Circ Cardiovasc Interv; 2017 Jun; 10(6):. PubMed ID: 28606999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.
    Bianco M; D'ascenzo F; Raposeiras Roubin S; Kinnaird T; Peyracchia M; Ariza-Solé A; Cerrato E; Manzano-Fernández S; Gravinese C; Templin C; Destefanis P; Velicki L; Luciano A; Xanthopoulou I; Rinaldi M; Rognoni A; Varbella F; Boccuzzi G; Omedè P; Montabone A; Bernardi A; Taha S; Rossini R; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Giustetto C; Garay A; Quadri G; Queija BC; Srdanovic I; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca Á; Cequier A; Alexopoulos D; Iñiguez-Romo A; Pozzi R; Assi EA; Valgimigli M
    Int J Cardiol; 2020 Feb; 301():200-206. PubMed ID: 31785951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.
    Yu J; Baber U; Mastoris I; Dangas G; Sartori S; Steg PG; Cohen DJ; Giustino G; Chandrasekhar J; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Colombo A; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1461-9. PubMed ID: 27478113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.
    Deharo P; Cuisset T
    Trends Cardiovasc Med; 2020 May; 30(4):198-202. PubMed ID: 31182263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
    Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
    Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
    Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
    Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.